Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

Medicus Pharma Ltd.

MDCXNASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. Share Consolidation Medicus Pharma Ltd. (the "Company") today announced that it will effect a fifty-to-one consolidation (the "Share Consolidation") of the Company's common shares, no par value (the "Common Shares"), to be effective on October 12, 2026.…

Filed Oct 7, 2026Accepted Oct 7, 2026, 4:05 PM EDTCIK 1997296Accession 0001062993-26-005226
Share

Company context

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and  accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are  developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Current securities

Recent company filings

  1. SCHEDULE 13D/A - filed by Bokhari Raza regarding Medicus Pharma Ltd.Nov 17, 2026
  2. 4 filingNov 17, 2026
  3. 4 filingNov 17, 2026
  4. 4 filingNov 17, 2026
  5. 424B3 filingNov 16, 2026

Registered securities in this filing

Medicus Pharma Ltd. · 8-K · Filed 2026-10-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common shares, no par value

Symbol
MDCX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: CR20261007_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_CommonSharesNoParValueMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, each exercisable for one common share at an exercise price of $4.64 per share

Symbol
MDCXW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: CR20261007_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_WarrantsEachExercisableForOneCommonShareAtAnExercisePriceOfFourPointSixFourPerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000106299326005226 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. Share Consolidation Medicus Pharma Ltd. (the "Company") today announced that it will effect a fifty-to-one consolidation (the "Share Consolidation") of the Company's common shares, no par value (the "Common Shares"), to be effective on October 12, 2026. The Share Consolidation is intended to increase the bid price of the Common Shares and to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Common Shares are expected to begin trading on a consolidated basis on The Nasdaq Capital Market at the commencement of trading on October 12, 2026, with a new CUSIP number of 58471K301 and a new ISIN of CA58471K3010. The Company's name will remain unchanged and the ticker symbol for the Common Shares will remain "MDCX." At the Company's 2026 Annual General and Special Meeting held on June 3, 2026, the Company's shareholders approved a proposal authorizing the Company's board of directors (the "Board") to effect a consolidation of the Common Shares at a ratio of up to fifty-to-one, with the exact ratio and timing to be determined by the Board in its sole discretion. Pursuant to such authorization, the Board has approved the Share Consolidation. Information for Shareholders As a result of the Share Consolidation, every 50 Common Shares issued and outstanding will be automatically exchanged for one new Common Share. The Share Consolidation will not modify any rights or preferences of the Common Shares. The Common Shares issued pursuant to the Share Consolidation will remain fully paid and non-assessable. The Share Consolidation will not change the voting power of holders of the outstanding Common Shares. No fractional shares will be issued in connection with the Share Consolidation. Shareholders who otherwise would be entitled to receive a fractional share because they hold a number of shares not evenly divisible by the Share Consolidation ratio will automatically be rounded down to the next whole share and cash will be paid in lieu for such fractional shares. Shareholders owning pre-Share Consolidation Common Shares via a bank, broker or other nominee will have their positions automatically adjusted to reflect the Share Consolidation and will not be required to take further action in connection with the Share Consolidation, subject to brokers' particular processes. For additional information on such processes, shareholders should contact their respective broker or nominee (as applicable). Similarly, registered shareholders holding pre-Share Consolidation Common Shares electronically in book-entry form are also not required to take further action in connection with the Share Consolidation. Impact on Other Equity Securities Proportionate adjustments will be made to the per share exercise price and the number of Common Shares issuable upon the exercise or conversion of outstanding equity awards, convertible securities and warrants, as well as to the number of Common Shares issued and issuable under the Company's equity incentive plans. Additional information about the Share Consolidation can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on May 4, 2026, which is available free of charge at the SEC's website, www.sec.gov/edgar, and on the Company's website at https://medicuspharma.com/investor-relations/sec-filings/. Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" or "forward-looking information" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, "forward-looking statements"), including, without limitation, statements regarding the effectiveness of the Share Consolidation and the timing thereof, the anticipated effect of the Share Consolidation on the bid price of the Common Shares and the Company's ability to regain and maintain compliance with the continued listing requirements of The Nasdaq Capital Market, the commencement of trading of the Common Shares on The Nasdaq Capital Market on a post-Share Consolidation basis and the timing thereof, the expected number of common shares outstanding following the Consolidation, the proportionate adjustments to be made to outstanding equity awards, convertible securities and warrants and the treatment of fractional shares. Forward-looking statements are often, but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2025, and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Common Shares. Forward-looking statements contained in this Current Report on Form 8-K are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.